[Skip to Content]
[Skip to Content Landing]
Citations 0
June 10, 1998

Rescreening of Cervical Papanicolaou Smears Using PAPNET

Author Affiliations

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(22):1785-1788. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-22-jac80008

To the Editor.— The article by Dr O'Leary and colleagues1 has important clinical implications. The results suggest that PAPNET-automated rescreening (Neuromedical Systems Inc, Suffern, NY) has little clinical utility since the cost does not justify the few incremental cases of cervical disease it may detect. This article confirms what many epidemiologists, clinicians, and scientists have suspected all along. Although the concept is sound, there is no automated rescreening technology to date that can address the poor sensitivity and specificity of the Papanicolaou (Pap) smear in cervical cancer screening.

First Page Preview View Large
First page PDF preview
First page PDF preview